Sign In
Buy KTTA
$0.460
+0.0159 (+3.58%)
At Close: Jul 31, 2026
Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
07:59am, Monday, 29'th Apr 2024
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company devel
Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
07:59am, Tuesday, 13'th Feb 2024
-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern Europ
-- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio -- SOUTH SAN FRANCISCO, Calif.
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
08:35am, Tuesday, 02'nd Jan 2024
-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 –
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
05:00pm, Thursday, 28'th Dec 2023
Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19.
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
05:19pm, Tuesday, 19'th Dec 2023
SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that it held its annual meeti
Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?
09:03am, Wednesday, 13'th Dec 2023
Pasithea Therapeutics (NASDAQ: KTTA ) stock is falling on Wednesday after the company's shares experienced major volatility on Tuesday. Investors watching KTTA stock will note that it closed out Tues
Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?
11:18am, Monday, 11'th Dec 2023
Pasithea Therapeutics (NASDAQ: KTTA ) stock is rocketing higher on Monday after the biotechnology company announced results from two preclinical trials of PAS-004. The first study saw positive results
Pasithea Therapeutics (Nasdaq: KTTA) announced positive preclinical efficacy in models conducted ahead of its planned Phase I, in-human trials in 1Q24.
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
04:27pm, Wednesday, 29'th Nov 2023
SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that its annual meeting of st
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
07:59am, Wednesday, 29'th Nov 2023
-- Company on track to submit PAS-004 IND application in current quarter -- -- Pasithea plans to begin PAS-004 Phase 1 dose escalation trial in advanced solid tumor patients harboring RAS, RAF and N
Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
08:30am, Thursday, 14'th Sep 2023
PALO ALTO, Calif. and MIAMI, Sept.
